TIAA CREF Investment Management LLC cut its stake in Myriad Genetics, Inc. (NASDAQ:MYGN) by 5.9% during the first quarter, Holdings Channel reports. The institutional investor owned 185,214 shares of the company’s stock after selling 11,698 shares during the period. TIAA CREF Investment Management LLC’s holdings in Myriad Genetics were worth $3,556,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of MYGN. Norges Bank purchased a new position in shares of Myriad Genetics during the fourth quarter valued at $14,319,000. Bank of New York Mellon Corp increased its position in shares of Myriad Genetics by 131.2% in the first quarter. Bank of New York Mellon Corp now owns 918,305 shares of the company’s stock valued at $17,632,000 after buying an additional 521,146 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Myriad Genetics by 4,174.4% in the first quarter. Principal Financial Group Inc. now owns 530,148 shares of the company’s stock valued at $10,179,000 after buying an additional 517,745 shares in the last quarter. First Trust Advisors LP increased its position in shares of Myriad Genetics by 32.3% in the first quarter. First Trust Advisors LP now owns 1,918,172 shares of the company’s stock valued at $36,829,000 after buying an additional 468,653 shares in the last quarter. Finally, Ameriprise Financial Inc. purchased a new position in shares of Myriad Genetics during the first quarter valued at $6,992,000.

Myriad Genetics, Inc. (NASDAQ MYGN) opened at 23.46 on Friday. The company has a market cap of $1.60 billion, a P/E ratio of 50.13 and a beta of 0.32. The company has a 50 day moving average of $24.67 and a 200-day moving average of $20.23. Myriad Genetics, Inc. has a one year low of $15.15 and a one year high of $32.05.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, May 2nd. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.24 by $0.03. Myriad Genetics had a net margin of 4.26% and a return on equity of 10.53%. The firm had revenue of $196.90 million for the quarter, compared to analyst estimates of $188.89 million. On average, equities analysts expect that Myriad Genetics, Inc. will post $1.01 earnings per share for the current fiscal year.

WARNING: “Myriad Genetics, Inc. (NASDAQ:MYGN) Stake Cut by TIAA CREF Investment Management LLC” was originally published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/07/27/myriad-genetics-inc-nasdaqmygn-stake-cut-by-tiaa-cref-investment-management-llc.html.

Several research firms have commented on MYGN. J P Morgan Chase & Co reissued an “underweight” rating and set a $16.00 price objective on shares of Myriad Genetics in a report on Friday, June 30th. Jefferies Group LLC reissued a “hold” rating and set a $21.00 price objective (up previously from $18.00) on shares of Myriad Genetics in a report on Wednesday, May 3rd. BidaskClub raised shares of Myriad Genetics from a “hold” rating to a “buy” rating in a report on Saturday, June 17th. Deutsche Bank AG increased their price objective on shares of Myriad Genetics from $15.00 to $20.00 and gave the company a “sell” rating in a report on Monday, May 8th. Finally, Cowen and Company reissued a “hold” rating and set a $25.00 price objective on shares of Myriad Genetics in a report on Friday, July 14th. Five investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $22.00.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.